Comparison of Two Types of Calcium (Ca²⁺) Ionophore Treatments for Oocyte Activation in Cases of Suboptimal Fertilization Potential ((Ca²⁺))
調査の概要
状態
詳細な説明
The introduction of ICSI has significantly improved fertilization rates worldwide from 15% to 70-80% between 1996 and 2019. Despite its use, total fertilization failure (TFF) still occurs in 1-5% of cases Oocyte activation deficiency (OAD) is a primary cause of TFF, preventing mature oocytes from undergoing activation and successful fertilization. This deficiency, which can originate from either the sperm or the oocyte, is estimated to contribute directly to 40% of ICSI failures , with potentially higher indirect contributions.
As infertility and ICSI cycles continue to rise, so does the frequency of TFF and OAD. While deficiencies in oocyte-derived factors are more challenging to address and likely involve pathways downstream of sperm-induced activation, the absence of oocyte activation due to deficient sperm-derived signals has been partially overcome through assisted oocyte activation (AOA) approaches. During fertilization, oocyte activation is initiated by sperm-specific phospholipase C zeta (PLCζ), which induces Ca²⁺ oscillations within the oocyte. A disruption in this mechanism is a leading cause of fertilization failure in mammals. Some male etiologies imply deficiencies in sperm PLCζ. In particular, cases of globozoospermia, where sperm lack phospholipase C zeta (PLCζ) and fail to initiate the necessary Ca2+ oscillations for fertilization, have been addressed and proven efficient with AOA. Assisted oocyte activation (AOA) approaches have been proposed as a clinical intervention and have demonstrated some success in compensating for sperm factor deficiencies, by replicating this Ca²⁺ release using mechanical, electrical, or chemical stimulation by Ca²⁺ ionophores. However, concerns regarding its non-physiological nature and incomplete understanding of Ca²⁺ signaling in fertilization limit its widespread implementation.
Ca2+ ionophores are chemical compounds that facilitate the transport of Ca²⁺ ions (Ca²⁺) across biological membranes, bypassing the cells' natural Ca²⁺ signaling mechanisms, therefore they have been applied as AOA biochemical approach. The two most used types of Ca²⁺ Ionophores, are a commercially available Ca2+ Ionophore, A23187 (also known as calcimycin, and is commercially available by Gynemed), a carboxylic antibiotic that binds and freely transports Ca2+ across all biological membranes, and Ionomycin, which is far more specific and potent for Ca²⁺ compared to A23187 and can activate and indirectly stimulate gene expression due to the activation of various Ca²⁺-dependent signaling pathways. Ca2+ signalling is not only essential for nuclear processes such as fertilization mechanisms and cortical granules release, but also for cytoplasmic events such as cytoskeletal rearrangement, mitochondrial function and energy production, and a role in oxidative balance. Although several studies have been published, including a Cochrane review, there have been few randomized controlled trials (RCTs) involving sibling oocytes at the MII stage. Many studies have either included in vitro-matured oocytes or were of retrospective nature, which complicates the interpretation of conclusions regarding the efficacy of the optimal method. Of note, two RCTs using sibling MIIs applied A23187 with no differences in fertilization rates, and only one in Ca²⁺ using Ionomycin which resulted in better fertilization outcomes. Use of CaCl2 in combination to Ca²⁺ ionophore seems to improve outcomes in relation to fertilization without impacting birth characteristics and congenital malformations of the 47 children born. However, safety studies involving preimplantation genetic testing for aneuploidy (PGT-A) on embryos derived from AOA have not been conducted, with only one retrospective report available. Given that for some couples using AOA would mean a last resource to obtain available embryos and for some a significant increase on the availability of embryos, it is crucial to assess both the safety and efficacy by analyzing ploidy and identifying the optimal protocol in this context.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:JONALYN EDADES, EMBA Healthcare Management
- 電話番号:026528000
- メール:jonalyn.edades@artfertilityclinics.com
研究連絡先のバックアップ
- 名前:barbara lawrenz, PhD
- 電話番号:026528000
- メール:barbara.lawrenz@artfertilityclinics.com
参加基準
適格基準
就学可能な年齢
- 大人
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Patients undergoing assisted reproductive technology cycles when ICSI is indicated.
- Patients with a minimum of 3 MII oocytes after denudation.
- Maternal age 18-43 years old.
- PGT-A cycles with only trophectoderm biopsies on day 5/6/7.
- BMI<35.
- Fresh and frozen immotile ejaculated sperm.
- Fresh and frozen TESE sperm (motile and immotile).
- Globozoospermia.
10. Couples undergoing ICSI due to poor fertilization history (≤30%), or previous fertilization failure.
Exclusion Criteria:
- PGT-M/SR cycles.
- Fresh and frozen motile ejaculated / FNA sperm.
- IVF inseminated oocytes.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:他の
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
他の:Group 1: Oocyte Activation (OA) CultActive
Oocytes are cultured immediately after injection in a pre-calibrated OA-CultActive dish for 15 min in CO2 incubator, then injected oocytes are rinsed well in culture dish/ Embryoscope slide in GT-culture medium.
Then transferred to the numbered droplet or well.
|
Oocytes are cultured immediately after injection in a pre-calibrated OA-CultActive dish for 15 min in CO2 incubator, then injected oocytes are rinsed well in culture dish/ Embryoscope slide in GT-culture medium.
Then transferred to the numbered droplet or well.
|
|
他の:Group 2: Oocyte Activation (OA) Ionomycin
Oocytes are placed immediately after injection in a pre-calibrated OA-Ionomycin dish (dish 1) for 7 - 10 min in CO2 incubator, then they are rinsed well and placed in another culture dish (dish 2) for 25 min in CO2 incubator.
Then MIIs are exposed again in OA-Ionomycin dish for 10 min, then they are rinsed well and placed into culture dish/ Embryoscope slide in GT-culture medium.
Then transferred to the numbered droplet or well.
|
Oocytes are placed immediately after injection in a pre-calibrated OA-Ionomycin dish (dish 1) for 7 - 10 min in CO2 incubator, then they are rinsed well and placed in another culture dish (dish 2) for 25 min in CO2 incubator.
Then MIIs are exposed again in OA-Ionomycin dish for 10 min, then they are rinsed well and placed into culture dish/ Embryoscope slide in GT-culture medium.
Then transferred to the numbered droplet or well.
|
|
他の:Group 3: Control
Oocytes are cultured as per routine practice after injection in culture dish/ Embryoscope slide in routine culture GT-culture medium.
|
Oocytes are cultured as per routine practice after injection in culture dish/ Embryoscope slide in routine culture GT-culture medium.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Fertilization rates and abnormal fertilization.
時間枠:16-20 hours post-insemination/ICSI
|
The primary endpoint is the proportion of metaphase II (MII) oocytes that achieve normal fertilisation (2 pronuclei; 2PN) following insemination or ICSI, compared across study groups.
Additionally, the incidence of abnormal fertilisation (e.g., 0PN, 1PN, ≥3PN) will be evaluated.
Fertilisation assessment will be performed at the standard time point of 16-20 hours post-insemination/ICSI.
|
16-20 hours post-insemination/ICSI
|
|
Oocyte Degeneration Rate
時間枠:24 hours post-ICSI
|
The proportion of metaphase II (MII) oocytes that undergo degeneration following ICSI across the study groups.
Degeneration will be assessed at the standard post-ICSI evaluation time point, and expressed as the percentage of injected oocytes exhibiting morphological signs of degeneration.
|
24 hours post-ICSI
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Usable Blastocyst Rate
時間枠:7 days post fertilization
|
The proportion of normally fertilised oocytes that develop into blastocysts deemed suitable for vitrification or transfer based on established morphological and developmental criteria.
The rate will be calculated as the number of usable blastocysts divided by the total number of fertilised oocytes (2PN) within each study group.
|
7 days post fertilization
|
|
Blastocyst Ploidy on Day 5, 6, or 7
時間枠:From enrollment to the end of treatment at 4 week
|
Assessment of chromosomal status of biopsied blastocysts using preimplantation genetic testing (PGT).
Ploidy results (euploid, aneuploid, mosaic) will be evaluated and compared across study groups to determine the influence of Ca²⁺ ionophore treatment on chromosomal integrity and embryo competence.
|
From enrollment to the end of treatment at 4 week
|
|
Blastocyst Quality at Time of Biopsy
時間枠:7 days post fertilization
|
Blastocyst quality will be assessed using the modified Gardner blastocyst grading scale, which evaluates blastocyst expansion stage, inner cell mass quality, and trophectoderm quality at the time of biopsy. The blastocyst expansion stage is scored from 1 to 6, where higher scores indicate a more expanded or hatched blastocyst. The inner cell mass and trophectoderm are graded from A to C, where A indicates the best quality, B indicates intermediate quality, and C indicates the lowest quality. Blastocyst quality scores will be compared across study groups to determine the impact of Ca²⁺ ionophore treatment on blastocyst development. |
7 days post fertilization
|
協力者と研究者
捜査官
- スタディディレクター:BARBARA LAWRENZ、ART Fertility Clinics LLC
出版物と役立つリンク
一般刊行物
- Capalbo A, Ottolini CS, Griffin DK, Ubaldi FM, Handyside AH, Rienzi L. Artificial oocyte activation with calcium ionophore does not cause a widespread increase in chromosome segregation errors in the second meiotic division of the oocyte. Fertil Steril. 2016 Mar;105(3):807-814.e2. doi: 10.1016/j.fertnstert.2015.11.017. Epub 2015 Dec 1.
- Kashir J, Ganesh D, Jones C, Coward K. Oocyte activation deficiency and assisted oocyte activation: mechanisms, obstacles and prospects for clinical application. Hum Reprod Open. 2022 Feb 7;2022(2):hoac003. doi: 10.1093/hropen/hoac003. eCollection 2022.
- Yeste M, Jones C, Amdani SN, Patel S, Coward K. Oocyte activation deficiency: a role for an oocyte contribution? Hum Reprod Update. 2016 Jan-Feb;22(1):23-47. doi: 10.1093/humupd/dmv040. Epub 2015 Sep 7.
- Ye Y, Li N, Yan X, Wu R, Zhou W, Cheng L, Li Y. Genetic analysis of embryo in a human case of spontaneous oocyte activation: a case report. Gynecol Endocrinol. 2020 Apr;36(4):294-296. doi: 10.1080/09513590.2019.1687671. Epub 2019 Nov 10.
- Yang X, Shu L, Cai L, Sun X, Cui Y, Liu J. Homozygous missense mutation Arg207Cys in the WEE2 gene causes female infertility and fertilization failure. J Assist Reprod Genet. 2019 May;36(5):965-971. doi: 10.1007/s10815-019-01418-9. Epub 2019 Mar 2.
- Tosti E, Menezo Y. Gamete activation: basic knowledge and clinical applications. Hum Reprod Update. 2016 Jun;22(4):420-39. doi: 10.1093/humupd/dmw014. Epub 2016 Jun 8.
- Tiegs AW, Tao X, Landis J, Zhan Y, Franasiak JM, Seli E, Wells D, Fragouli E, Scott RT Jr. Sperm Mitochondrial DNA Copy Number Is Not a Predictor of Intracytoplasmic Sperm Injection (ICSI) Cycle Outcomes. Reprod Sci. 2020 Jun;27(6):1350-1356. doi: 10.1007/s43032-020-00163-0. Epub 2020 Jan 28.
- Tesarik J, Rienzi L, Ubaldi F, Mendoza C, Greco E. Use of a modified intracytoplasmic sperm injection technique to overcome sperm-borne and oocyte-borne oocyte activation failures. Fertil Steril. 2002 Sep;78(3):619-24. doi: 10.1016/s0015-0282(02)03291-0.
- Santella L, Dale B. Assisted yes, but where do we draw the line? Reprod Biomed Online. 2015 Oct;31(4):476-8. doi: 10.1016/j.rbmo.2015.06.013. Epub 2015 Jul 3.
- Sang Q, Li B, Kuang Y, Wang X, Zhang Z, Chen B, Wu L, Lyu Q, Fu Y, Yan Z, Mao X, Xu Y, Mu J, Li Q, Jin L, He L, Wang L. Homozygous Mutations in WEE2 Cause Fertilization Failure and Female Infertility. Am J Hum Genet. 2018 Apr 5;102(4):649-657. doi: 10.1016/j.ajhg.2018.02.015. Epub 2018 Mar 29.
- Montag M, Koster M, van der Ven K, Bohlen U, van der Ven H. The benefit of artificial oocyte activation is dependent on the fertilization rate in a previous treatment cycle. Reprod Biomed Online. 2012 May;24(5):521-6. doi: 10.1016/j.rbmo.2012.02.002. Epub 2012 Feb 10.
- Mateizel I, Verheyen G, Van de Velde H, Tournaye H, Belva F. Obstetric and neonatal outcome following ICSI with assisted oocyte activation by calcium ionophore treatment. J Assist Reprod Genet. 2018 Jun;35(6):1005-1010. doi: 10.1007/s10815-018-1124-6. Epub 2018 Feb 1.
- Karabulut S, Aksunger O, Ata C, Sagiroglu Y, Keskin I. Artificial oocyte activation with calcium ionophore for frozen sperm cycles. Syst Biol Reprod Med. 2018 Oct;64(5):381-388. doi: 10.1080/19396368.2018.1452311. Epub 2018 Apr 5.
- Kashir J, Nomikos M, Lai FA. Phospholipase C zeta and calcium oscillations at fertilisation: The evidence, applications, and further questions. Adv Biol Regul. 2018 Jan;67:148-162. doi: 10.1016/j.jbior.2017.10.012. Epub 2017 Oct 27.
- Kashir J, Mistry BV, BuSaleh L, Abu-Dawas R, Nomikos M, Ajlan A, Abu-Dawud R, AlYacoub N, AlHassan S, Lai FA, Assiri AM, Coskun S. Phospholipase C zeta profiles are indicative of optimal sperm parameters and fertilisation success in patients undergoing fertility treatment. Andrology. 2020 Sep;8(5):1143-1159. doi: 10.1111/andr.12796. Epub 2020 May 20.
- Kashir J. Increasing associations between defects in phospholipase C zeta and conditions of male infertility: not just ICSI failure? J Assist Reprod Genet. 2020 Jun;37(6):1273-1293. doi: 10.1007/s10815-020-01748-z. Epub 2020 Apr 14.
- Kamath MS, Vogiatzi P, Sunkara SK, Woodward B. Oocyte activation for women following intracytoplasmic sperm injection (ICSI). Cochrane Database Syst Rev. 2024 Dec 20;12(12):CD014040. doi: 10.1002/14651858.CD014040.pub2.
- ESHRE Add-ons working group; Lundin K, Bentzen JG, Bozdag G, Ebner T, Harper J, Le Clef N, Moffett A, Norcross S, Polyzos NP, Rautakallio-Hokkanen S, Sfontouris I, Sermon K, Vermeulen N, Pinborg A. Good practice recommendations on add-ons in reproductive medicinedagger. Hum Reprod. 2023 Nov 2;38(11):2062-2104. doi: 10.1093/humrep/dead184.
- Heindryckx B, De Gheselle S, Gerris J, Dhont M, De Sutter P. Efficiency of assisted oocyte activation as a solution for failed intracytoplasmic sperm injection. Reprod Biomed Online. 2008 Nov;17(5):662-8. doi: 10.1016/s1472-6483(10)60313-6.
- Ebner T, Montag M; Oocyte Activation Study Group; Montag M, Van der Ven K, Van der Ven H, Ebner T, Shebl O, Oppelt P, Hirchenhain J, Krussel J, Maxrath B, Gnoth C, Friol K, Tigges J, Wunsch E, Luckhaus J, Beerkotte A, Weiss D, Grunwald K, Struller D, Etien C. Live birth after artificial oocyte activation using a ready-to-use ionophore: a prospective multicentre study. Reprod Biomed Online. 2015 Apr;30(4):359-65. doi: 10.1016/j.rbmo.2014.11.012. Epub 2014 Dec 9.
- Boulet SL, Mehta A, Kissin DM, Warner L, Kawwass JF, Jamieson DJ. Trends in use of and reproductive outcomes associated with intracytoplasmic sperm injection. JAMA. 2015 Jan 20;313(3):255-63. doi: 10.1001/jama.2014.17985.
- Bonte D, Ferrer-Buitrago M, Dhaenens L, Popovic M, Thys V, De Croo I, De Gheselle S, Steyaert N, Boel A, Vanden Meerschaut F, De Sutter P, Heindryckx B. Assisted oocyte activation significantly increases fertilization and pregnancy outcome in patients with low and total failed fertilization after intracytoplasmic sperm injection: a 17-year retrospective study. Fertil Steril. 2019 Aug;112(2):266-274. doi: 10.1016/j.fertnstert.2019.04.006. Epub 2019 May 24.
- Bassiri F, Nasr-Esfahani MH, Forozanfar M, Tavalaee M. Relationship between Sperm Parameters with Sperm Function Tests in Infertile Men with at Least One Failed Cycle after Intracytoplasmic Sperm Injection Cycle. Int J Fertil Steril. 2020 Jan;13(4):324-329. doi: 10.22074/ijfs.2020.5750. Epub 2019 Nov 11.
- Aydinuraz B, Dirican EK, Olgan S, Aksunger O, Erturk OK. Artificial oocyte activation after intracytoplasmic morphologically selected sperm injection: A prospective randomized sibling oocyte study. Hum Fertil (Camb). 2016 Dec;19(4):282-288. doi: 10.1080/14647273.2016.1240374. Epub 2016 Oct 13.
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- 2503-ABU-008-NH
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。